Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05556
[1]
m6A modification hsa-miR-375-3p hsa-miR-375-3p METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-375-3p PDK1  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
m6A Target hsa-miR-375-3p
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-375-3p microRNA View Details
Regulated Target PDH kinase 1 (PDK1) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Silencing METTL3 inhibited m6A level and decreased the binding of DGCR8 to pri-miR-375 and further limited hsa-miR-375-3p expression. METTL3-mediated m6A modification promoted VSMC phenotype transformation and made Atherosclerosis (AS) plaques more vulnerable via the miR-375-3p/PDH kinase 1 (PDK1) axis.
Responsed Disease Atherosclerosis ICD-11: BD40
In-vitro Model
MOVAS (Mouse aortic vascular smooth muscle cell lines)
In-vivo Model The normal group consisted of C57BL/6J mice on normal diet and the HFD group consisted of ApoE C57BL/6J mice on HFD (containing 10% lard oil, 4% milk powder, 2% cholesterol, and 0.5% sodium cholate). Four weeks after HFD feeding, the mice were injected with 200 ul lentivirus containing 1 × 10-/--/-8 TU (lentivirus carrying sh-METTL3 or sh-NC; designed and constructed by GENCHEM (Shanghai, China)) via tail vein. Six weeks after transfection, all mice were euthanized by a tail vein injection of 200 mg/kg pentobarbital sodium.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
PDH kinase 1 (PDK1) 99 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Dichloroacetate Phase 4 [2]
Synonyms
2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Heteroaryl-carboxamide derivative 4 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 27(6)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name Pyrazole derivative 61 Patented [3]
Synonyms
PMID25684022-Compound-US20090111799
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2000 nM
External Link
 Compound Name PMID25684022-Compound-WO2011137219 37(4-6) Patented [3]
MOA Inhibitor
Activity IC50 = 110 nM
External Link
 Compound Name Heteroaryl-carboxamide derivative 3 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 26(5)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name Pyrimidine derivative 3 Patented [3]
Synonyms
PMID25684022-Compound-WO2011076327
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 120 nM
External Link
 Compound Name Heterocyclic derivative 15 Patented [3]
Synonyms
PMID25684022-Compound-WO2012044157 4(58)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Thieno[3,2-c]pyridine-7-carboxamide derivative 2 Patented [3]
Synonyms
PMID25684022-Compound-WO2006106326c2
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 160 nM
External Link
 Compound Name Heteroaryl-carboxamide derivative 9 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 32(20)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name Thiazole carboxamide derivative 24 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 18(27)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Heterocyclic derivative 12 Patented [3]
Synonyms
PMID25684022-Compound-WO2012044157 1(1.5)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name PMID25684022-Compound-US20120277229 41(1.3) Patented [3]
MOA Inhibitor
Activity IC50 = 280 nM
External Link
 Compound Name Heterocyclic derivative 17 Patented [3]
Synonyms
PMID25684022-Compound-WO2012044157 6(360)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Thiazole carboxamide derivative 27 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 21(40)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-WO2008079988 Patented [3]
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name Pyridinone carboxamide derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2010007116
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 1000 nM
External Link
 Compound Name Heterocyclic derivative 4 Patented [3]
Synonyms
PMID25684022-Compound-US20120208819 1(1.5)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Thieno[3,2-c]pyridine-7-carboxamide derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2006106326c1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 350 nM
External Link
 Compound Name Thiazole carboxamide derivative 9 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 18(27)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-WO2009153313 Patented [3]
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name PMID25684022-Compound-US20120277229 40(1.2) Patented [3]
MOA Inhibitor
Activity IC50 = 160 nM
External Link
 Compound Name Thiazole carboxamide derivative 12 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 21(40)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-WO2004087707 Patented [3]
MOA Inhibitor
Activity IC50 = 320 to 32000 nM
External Link
 Compound Name Benzimidazole and imidazopyridine derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2011006567
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.1 to 10 nM
External Link
 Compound Name Thiazole carboxamide derivative 14 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 24(45)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-US20130053382 38(5-7) Patented [3]
MOA Inhibitor
Activity IC50 = 85 nM
External Link
 Compound Name Heterocyclic derivative 9 Patented [3]
Synonyms
PMID25684022-Compound-US20120208819 6(360)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Heterocyclic derivative 10 Patented [3]
Synonyms
PMID25684022-Compound-US20120208819 7(402)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Thiazole carboxamide derivative 11 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 20(38)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-US20130053382 36(3-5) Patented [3]
MOA Inhibitor
Activity IC50 = 170 nM
External Link
 Compound Name PMID25684022-Compound-US20120277229 45(1.5) Patented [3]
MOA Inhibitor
Activity IC50 = 780 nM
External Link
 Compound Name Thiazole carboxamide derivative 29 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 24(45)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-WO2008005457 Patented [3]
MOA Inhibitor
Activity IC50 < 500 nM
External Link
 Compound Name Heteroaryl-carboxamide derivative 2 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 25(3)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name Thiazole carboxamide derivative 7 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 16(16)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Heterocyclic derivative 11 Patented [3]
Synonyms
PMID25684022-Compound-US20120208819 8(443)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name PMID25684022-Compound-US20120277229 39(1.1) Patented [3]
MOA Inhibitor
Activity IC50 = 140 nM
External Link
 Compound Name Heterocyclic derivative 8 Patented [3]
Synonyms
PMID25684022-Compound-US20120208819 5(355)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Thiazole carboxamide derivative 20 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 14(14)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-WO2011137219 36(3-5) Patented [3]
MOA Inhibitor
Activity IC50 = 170 nM
External Link
 Compound Name PMID25684022-Compound-WO2010127754 Patented [3]
MOA Inhibitor
Activity IC50 = 0.5 to 1000 nM
External Link
 Compound Name Indazole derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2003064397
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 to 140 nM
External Link
 Compound Name Heterocyclic-carboxamide derivative 2 Patented [3]
Synonyms
PMID25684022-Compound-WO2011044157
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 1000 nM
External Link
 Compound Name Heterocyclic derivative 6 Patented [3]
Synonyms
PMID25684022-Compound-US20120208819 3(7.6)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Imidazo quinoline derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2008054238
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 34 to 330 nM
External Link
 Compound Name Thiazole carboxamide derivative 16 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 10(4)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-WO2012135799 42(1.4) Patented [3]
MOA Inhibitor
Activity IC50 = 300 nM
External Link
 Compound Name Bis-indolylmaleimide derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2005041953
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 750 to 14000 nM
External Link
 Compound Name Thiazole carboxamide derivative 23 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 17(23)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Heterocyclic derivative 14 Patented [3]
Synonyms
PMID25684022-Compound-WO2012044157 3(7.6)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Thiazole carboxamide derivative 18 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 12(12)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Heterocyclic derivative 18 Patented [3]
Synonyms
PMID25684022-Compound-WO2012044157 7(402)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Thiazole carboxamide derivative 17 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 11(5)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Heteroaryl-carboxamide derivative 6 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 29(8)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name Thiazole carboxamide derivative 19 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 13(13)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Thiazole carboxamide derivative 4 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 13(13)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Heteroaryl-carboxamide derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 24(47)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name Heterocyclic derivative 13 Patented [3]
Synonyms
PMID25684022-Compound-WO2012044157 2(2.4)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Thiazole carboxamide derivative 2 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 11(5)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Pyrazolopyridines and imidazopyridine derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2010017047
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 30000 nM
External Link
 Compound Name Dibenzo [c,f]-[2,7]naphthyridine derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-US20070135429
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 60 to 7500 nM
External Link
 Compound Name PMID25684022-Compound-WO2011137219 38(5-7) Patented [3]
MOA Inhibitor
Activity IC50 = 85 nM
External Link
 Compound Name Benzonaphthyridine derivative 2 Patented [3]
Synonyms
PMID25684022-Compound-WO2008109613
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8 nM
External Link
 Compound Name Heterocyclic derivative 5 Patented [3]
Synonyms
PMID25684022-Compound-US20120208819 2(2.4)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Thiazole carboxamide derivative 25 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 19(36)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 50 nM
External Link
 Compound Name Thiazole carboxamide derivative 10 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 19(36)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 50 nM
External Link
 Compound Name Thiazole carboxamide derivative 22 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 16(16)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Heteroaryl-carboxamide derivative 5 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 28(7)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name PMID25684022-Compound-WO2008107444 Patented [3]
MOA Inhibitor
Activity IC50 <= 1000 nM
External Link
 Compound Name Heteroaryl-carboxamide derivative 7 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 30(12)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name PMID25684022-Compound-WO2011137219 35(1-11) Patented [3]
MOA Inhibitor
Activity IC50 = 33 nM
External Link
 Compound Name Pyrimidinone derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2010007114
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 1000 nM
External Link
 Compound Name Thiazole carboxamide derivative 21 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 15(15)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Thiazole carboxamide derivative 8 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 17(23)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name 1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2010120854
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7.6 nM
External Link
 Compound Name Thiazole carboxamide derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 10(4)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Thiazole carboxamide derivative 15 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 9(2)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 nM
External Link
 Compound Name Thiazole carboxamide derivative 28 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 23(41)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-WO2012135799 43(1.5) Patented [3]
MOA Inhibitor
Activity IC50 = 780 nM
External Link
 Compound Name Thiazole carboxamide derivative 3 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 12(12)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name PMID25684022-Compound-US20120277229 44(1.4) Patented [3]
MOA Inhibitor
Activity IC50 = 300 nM
External Link
 Compound Name Heterocyclic derivative 16 Patented [3]
Synonyms
PMID25684022-Compound-WO2012044157 5(355)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name PMID25684022-Compound-WO2006015124 Patented [3]
MOA Inhibitor
Activity IC50 = 1000 to 5000 nM
External Link
 Compound Name Heterocyclic-carboxamide derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2010065384
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 30000 nM
External Link
 Compound Name PMID25684022-Compound-US20130053382 35(1-11) Patented [3]
MOA Inhibitor
Activity IC50 = 33 nM
External Link
 Compound Name Heteroaryl-carboxamide derivative 10 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 33(21)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name Benzonaphthyridine derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2008109599
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8 nM
External Link
 Compound Name Thiazole carboxamide derivative 5 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 14(14)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Thiazole carboxamide derivative 26 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 20(38)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Heterocyclic derivative 7 Patented [3]
Synonyms
PMID25684022-Compound-US20120208819 4(58)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name Heteroaryl-carboxamide derivative 8 Patented [3]
Synonyms
PMID25684022-Compound-WO2012058176 31(13)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 <= 50 nM
External Link
 Compound Name Heterocyclic derivative 19 Patented [3]
Synonyms
PMID25684022-Compound-WO2012044157 8(443)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 5000 nM
External Link
 Compound Name PMID25684022-Compound-US20130053382 37(4-6) Patented [3]
MOA Inhibitor
Activity IC50 = 110 nM
External Link
 Compound Name PMID25684022-Compound-EP20041486488 Patented [3]
MOA Inhibitor
Activity IC50 = 20000 nM
External Link
 Compound Name Thiazole carboxamide derivative 30 Patented [3]
Synonyms
PMID25684022-Compound-WO2012036974 9(2)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 nM
External Link
 Compound Name Thiazole carboxamide derivative 6 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 15(15)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Indolinone derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-US200607105563
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 520 nM
External Link
 Compound Name Thiazole carboxamide derivative 13 Patented [3]
Synonyms
PMID25684022-Compound-US20130165450 23(41)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 250 nM
External Link
 Compound Name Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1 Patented [3]
Synonyms
PMID25684022-Compound-WO2010019637
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 to 10000 nM
External Link
BD40: Atherosclerosis 125 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Acipimox Approved [4]
Synonyms
Monted; Nedios; Olbemox; Olbetam; K 9321
    Click to Show/Hide
External Link
 Compound Name LAROPIPRANT Phase 4 [5]
Synonyms
571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B
    Click to Show/Hide
External Link
 Compound Name Anacetrapib Phase 3 [6]
Synonyms
MK0859; Anacetrapib (USAN); MK-0859
    Click to Show/Hide
External Link
 Compound Name LY2157299 Phase 2/3 [7]
Synonyms
Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
    Click to Show/Hide
External Link
 Compound Name PACTIMIBE Phase 2/3 [8]
Synonyms
189198-30-9; UNII-D874R9PZ9T; D874R9PZ9T; CHEMBL478858; Pactimibe [INN:BAN]; [7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid; (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid; AC1MIXTD; SCHEMBL282098; CTK0H7032; DTXSID80172315; TXIIZHHIOHVWJD-UHFFFAOYSA-N; ZINC1545445; BDBM50263192; DB12971; 2-[7-(2,2-Dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo L-5-yl]acetic acid; AN-30445; 198P309
    Click to Show/Hide
External Link
 Compound Name LY3012212 Phase 2 [9]
Synonyms
Icrucumab
    Click to Show/Hide
External Link
 Compound Name K-134 Phase 2 [10]
Synonyms
SULBACTAM; 68373-14-8; sulbactam acid; Sulbactamum; Betamaze; Penicillanic Acid Sulfone; (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; penicillanic acid 1,1-dioxide; UNII-S4TF6I2330; CP 45899; CHEMBL403; CHEBI:9321; S4TF6I2330; Sulbactam;Penicillanic acid sulfone; (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; Sulbactam [INN:BAN]; CP-45,899; Sulbactamum [INN-Latin]; DSSTox_CID_3605; DSSTox_RID_77104
    Click to Show/Hide
External Link
 Compound Name BMS-582949 Phase 2 [11]
Synonyms
623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; BMS582949 free base; PS 540446
    Click to Show/Hide
External Link
 Compound Name VB-201 Phase 2 [12]
External Link
 Compound Name CSL-112 Phase 2 [13]
Synonyms
Reconstituted HDL (acute coronary syndrome), CSL
    Click to Show/Hide
External Link
 Compound Name MK-1903 Phase 2 [14]
Synonyms
Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co
    Click to Show/Hide
External Link
 Compound Name DRL-17822 Phase 2 [15]
Synonyms
CETP inhibitor (dyslipidemia/atherosclerosis/cardiovascular diseases), Dr Reddy's
    Click to Show/Hide
External Link
 Compound Name PRC-4016 Investigative [16]
External Link
 Compound Name K-604 Phase 2 [17]
Synonyms
BDBM86691
    Click to Show/Hide
External Link
 Compound Name Revacept Phase 2 [18]
Synonyms
Arterial thrombosis treatment, Trigen; PR-15; Antiplatelet protein therapy (arterial thrombosis/atherosclerosis), Trigen
    Click to Show/Hide
External Link
 Compound Name DVC1-0101 Phase 2 [19]
Synonyms
Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University
    Click to Show/Hide
External Link
 Compound Name ATL-313 Phase 1/2 [20]
Synonyms
DE-112; ATL-313 (ocular disease), Adenosine Therapeutics; ATL-313 (ocular disease), Clinical Data
    Click to Show/Hide
External Link
 Compound Name PSI-697 Phase 1 [21]
Synonyms
UNII-LH1XC916ME; 851546-61-7; LH1XC916ME; CHEMBL219046; 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid; 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid; SCHEMBL43527; DIEPFYNZGUUVHD-UHFFFAOYSA-N; ZINC28603970; BDBM50201984; AKOS032945074; CS-5867; DB12211; HY-15526; LS-193902; 2-(4-chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]-quinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic
    Click to Show/Hide
External Link
 Compound Name SLV-342 Phase 1 [22]
External Link
 Compound Name LXR 623 Phase 1 [23]
Synonyms
LXR-623
    Click to Show/Hide
External Link
 Compound Name ATR-101 Phase 1 [24]
External Link
 Compound Name MDCO-216 Phase 1 [25]
External Link
 Compound Name XL-041 Phase 1 [26]
Synonyms
XCT-0179628; XCT-628; XL-652; XL-652); LXR modulator, X-Ceptor Therapeutics; LXR modulators, Exelixis/Sankyo; Liver X receptormodulator, Exelixis/Sankyo; Liver X receptor modulator, X-Ceptor; LXR agonist (atherosclerosis), BMS/Exelixis; LXR modulators, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulator, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulators (cardiovascular disorders), Exelixis/Bristol-Myers Squibb
    Click to Show/Hide
External Link
 Compound Name BMS-852927 Phase 1 [27]
External Link
 Compound Name CS-8080 Phase 1 [28]
Synonyms
Liver X receptor modulator (artherosclerosis), Daiichi Sankyo Inc; LXR modulator (anti-arteriosclerotic), Daiichi Sankyo Inc
    Click to Show/Hide
External Link
 Compound Name ISIS-APOCIII Phase 1 [29]
External Link
 Compound Name Rilapladib Phase 1 [30]
External Link
 Compound Name BMS-779788 Phase 1 [31]
External Link
 Compound Name BAY-60-5521 Phase 1 [32]
Synonyms
CETP inhibitors (dyslipidemia), Bayer; Cholesteryl ester transfer protein inhibitors (dyslipidemia), Bayer
    Click to Show/Hide
External Link
 Compound Name Quinazoline derivative 13 Patented [33]
Synonyms
PMID26936077-Compound-24
    Click to Show/Hide
External Link
 Compound Name Darapladib Discontinued in Phase 3 [34]
Synonyms
SB 480848; Darapladib (USAN)
    Click to Show/Hide
External Link
 Compound Name Acifran Discontinued in Phase 3 [35]
Synonyms
Reductol; AY-25712
    Click to Show/Hide
External Link
 Compound Name ET-642 Discontinued in Phase 2 [36]
Synonyms
ETC-642; RLT peptide, Esperion; RLT peptide, Pfizer
    Click to Show/Hide
External Link
 Compound Name SQ-32709 Discontinued in Phase 2 [37]
Synonyms
farnesyl diphosphate; farnesyl pyrophosphate; (2E,6E)-Farnesyl diphosphate; trans,trans-Farnesyl diphosphate; all-trans-Farnesyl pyrophosphate; (all-E)-Farnesyl diphosphate; (E,E)-Farnesyl pyrophosphate; (2E,6E)-Farnesyl pyrophosphate; trans-Farnesyl pyrophosphate; 2-trans,6-trans-Farnesyl pyrophosphate; farnesyl-PP; (E,E)-Farnesyl diphosphate; 2-trans,6-trans-farnesyl diphosphate; trans-trans-farnesyl diphosphate; UNII-79W6B01D07; CHEBI:17407; trans,trans-Farnesyl pyrophosphate; Sq 32709; 13058-04-3; CHEMBL69330
    Click to Show/Hide
External Link
 Compound Name CETi-1 Discontinued in Phase 2 [38]
Synonyms
Cholesteryl Ester Transfer Protein Vaccine; CETP vaccine, T Cell Sciences; Vaccine (CETP), AVANT; Vaccine (CETP), T Cell Sciences; Vaccine (atherosclerosis), T Cell Sciences
    Click to Show/Hide
External Link
 Compound Name Gantofiban Discontinued in Phase 2 [39]
Synonyms
CHEMBL78871; BDBM50092103; (4-{3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester(EMD-122347); (4-{(R)-3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester
    Click to Show/Hide
External Link
 Compound Name FCP-3P1 Discontinued in Phase 2 [40]
Synonyms
CardioRex; Antihyperlipidemic, Forbes Medi-Tech
    Click to Show/Hide
External Link
 Compound Name Lifibrol Discontinued in Phase 2 [41]
Synonyms
K-12148; U-83860; (R)-Lifibrol; (S)-Lifibrol; (S)-Lifibrol methyl ester
    Click to Show/Hide
External Link
 Compound Name TA-7552 Discontinued in Phase 2 [42]
Synonyms
TA 7552; 104756-72-1; 1-(3,4-Dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8-trimethoxynaphthalene; AC1L2U74; SCHEMBL8688163; DTXSID60146695; DTCYXOLBEPGOHV-UHFFFAOYSA-N; HY-100253; CS-0018404; dimethyl 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxynaphthalene-2,3-dicarboxylate; 2,3-Naphthalenedicarboxylic acid, 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxy-, dimethyl ester
    Click to Show/Hide
External Link
 Compound Name RUS 3108 Discontinued in Phase 1 [43]
External Link
 Compound Name GR-328713 Discontinued in Phase 1 [44]
Synonyms
GW-320449X; GW-328713X
    Click to Show/Hide
External Link
 Compound Name RG7418 Discontinued in Phase 1 [45]
Synonyms
BI204
    Click to Show/Hide
External Link
 Compound Name PF-3052334 Discontinued in Phase 1 [46]
Synonyms
SCHEMBL3959323
    Click to Show/Hide
External Link
 Compound Name Goxalapladib Discontinued in Phase 1 [47]
Synonyms
Goxalapladib < USAN; 2-[2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,4-dihydro-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[4'-(trifluoromethyl)biphenyl-4-ylmethyl]acetamide
    Click to Show/Hide
External Link
 Compound Name AC3056 Discontinued in Phase 1 [48]
External Link
 Compound Name PF-3185043 Discontinued in Phase 1 [49]
External Link
 Compound Name GSK568859 Discontinued in Phase 1 [50]
External Link
 Compound Name NICANARTINE Discontinued in Phase 1 [51]
Synonyms
MRZ-3/124; 2,6-Di-tert-butyl-4-[3-(3-pyridylmethoxy)propyl]phenol
    Click to Show/Hide
External Link
 Compound Name LG-101280 Discontinued in Phase 1 [52]
Synonyms
LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly
    Click to Show/Hide
External Link
 Compound Name PF-3491165 Discontinued in Phase 1 [53]
Synonyms
PF-03491165
    Click to Show/Hide
External Link
 Compound Name SB-435495 Discontinued in Phase 1 [54]
External Link
 Compound Name P-0654 Discontinued in Phase 1 [55]
Synonyms
P-0655
    Click to Show/Hide
External Link
 Compound Name CL-277082 Discontinued in Phase 1 [56]
Synonyms
UNII-KOF50RA8PQ; KOF50RA8PQ; CHEMBL277986; 3-(2,4-difluorophenyl)-1-[4-(2,2-dimethylpropyl)benzyl]-1-heptylurea; Ddpmhu; AC1Q5MV2; AC1L2PE2; SCHEMBL408973; CTK8D5698; BDBM50022279; ZINC36330844; CL 277082; N'-(2,4-DIFLUOROPHENYL)-N-HEPTYL-N-(4-NEOPENTYLBENZYL)UREA; Urea, N'-(2,4-difluorophenyl)-N-((4-(2,2-dimethylpropyl)phenyl)methyl)-N-heptyl-; 3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea; 3-(2,4-Difluoro-phenyl)-1-[4-(2,2-dimethyl-propyl)-benzyl]-1-heptyl-urea
    Click to Show/Hide
External Link
 Compound Name LF-08-0133 Discontinued in Phase 1 [57]
External Link
 Compound Name PF-807925 Discontinued in Phase 1 [58]
External Link
 Compound Name F-1394 Discontinued in Phase 1 [59]
Synonyms
AC1OCF5R; SCHEMBL4296509; [(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate
    Click to Show/Hide
External Link
 Compound Name CP-800569 Discontinued in Phase 1 [60]
Synonyms
(2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol
    Click to Show/Hide
External Link
 Compound Name APP-018 Discontinued in Phase 1 [61]
Synonyms
D-4F; Apolipoprotein A1 mimetic (atherosclerosis), Bruin Pharma; Apolipoprotein A1 mimetic (atherosclerosis),Novartis
    Click to Show/Hide
External Link
 Compound Name Nobiletin Preclinical [62]
Synonyms
478-01-3; Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; UNII-D65ILJ7WLY; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; NSC-76751; D65ILJ7WLY; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one; CHEMBL76447; Nobiletin (Hexamethoxyflavone); CHEBI:7602; NSC76751; MFCD03273560; Flavone, 5,6,7,8,3',4'-hexamethoxy; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; SMR000156231; CCRIS 9012; NSC 76751; CPD000156231; Nobiletin, >=97%; Spectrum2_001697; Spectrum3_000921; Spectrum4_001020; KBioGR_001519; MLS000574877; MLS000759462; MLS000877030; MLS001424129; Nobiletin, analytical standard; SCHEMBL244029; SPECTRUM1505268; SPBio_001654; MEGxp0_000930; ACon1_000921; KBio3_001922; DTXSID30197275; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one; HMS2051D09; HMS2234A09; HMS3373C14; HMS3393D09; HMS3651G20; HY-N0155; ZINC1531669; 3'4'5,6,7,8-Hexamethoxyflavone; 3,4,5,6,7,8-Hexamethoxyflavone; ANW-42631; BDBM50338976; CCG-38781; CN0043; LMPK12111468; NSC618903; STL565829; AKOS015965334; NOBILETIN, 20% (Technical Grade); AC-1023; CS-5518; MCULE-1015144950; NC00186; NSC-618903; SDCCGMLS-0066776.P001; NCGC00095703-01; NCGC00095703-02; NCGC00169228-01; 5,6,7,8,3'',4''-hexamethoxyflavone; AK168175; AS-17452; NCI60_041691; DB-050181; FT-0686667; N0871; N1311; S2333; SW197566-2; V0181; C10112; SR-01000712262; Q-100511; Q2402963; SR-01000712262-5; BRD-K06753942-001-02-0; 2-(3,4-Dimethoxy-phenyl)-5,6,7,8-tetramethoxy-chromen-4-one; 4H-1-Benzopyran-4-one,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 9CI; 3 inverted exclamation mark ,4 inverted exclamation mark ,5,6,7,8-HEXAMETHOXYFLAVONE; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (9CI)
    Click to Show/Hide
External Link
 Compound Name Quinoxaline Preclinical [63]
Synonyms
WYE-111672; WYE-672
    Click to Show/Hide
External Link
 Compound Name HL-004 Preclinical [64]
Synonyms
TS-962
    Click to Show/Hide
External Link
 Compound Name ETX-6107 Preclinical [65]
Synonyms
ETS-6107; ETS-6114; Antihypercholesterolemic agents (atherosclerosis), e-Therapeutics
    Click to Show/Hide
External Link
 Compound Name BAY-38-1315 Preclinical [66]
Synonyms
BAY-19-4789
    Click to Show/Hide
External Link
 Compound Name 2164U90 Terminated [67]
Synonyms
BW-2164; BW-2164U90
    Click to Show/Hide
External Link
 Compound Name GT-16-239 Terminated [68]
External Link
 Compound Name Cholazol Terminated [69]
Synonyms
Cholestran
    Click to Show/Hide
External Link
 Compound Name BB-476 Terminated [70]
External Link
 Compound Name CGP-43371 Terminated [71]
Synonyms
Cgp 43371; UNII-V97741GKF2; V97741GKF2; 123036-23-7; cgp43371; N,15-Didehydro-15-deoxo-1-deoxy-1,15-epoxy-4-O-methyl-3-(4-((2,4,6-trimethyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)
    Click to Show/Hide
External Link
 Compound Name AL-0671 Terminated [72]
Synonyms
AL-0670
    Click to Show/Hide
External Link
 Compound Name BIBX-79 Terminated [73]
Synonyms
175033-26-8; AC1L9UY2; BIBX 79; SCHEMBL8046646; SCHEMBL3363189; CHEMBL2377448; CHEMBL3765649; MolPort-028-951-512; ZINC59696570; ZINC238856506; ZINC100502012; AKOS034800865; MCULE-9414485243; EN300-155171; Z1768160684; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methyl-benzamide; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methylbenzamide; 4-Chloro-N-[4-(4-dimethylaminomethyl-phenyl)-cyclohexyl]-N-methyl-benzamide
    Click to Show/Hide
External Link
 Compound Name CI-999 Terminated [74]
Synonyms
PD-138142-15
    Click to Show/Hide
External Link
 Compound Name Bio-Flow Terminated [75]
External Link
 Compound Name CGS-24565 Terminated [76]
Synonyms
Cgs 24565; 136583-72-7; N,15-Didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)
    Click to Show/Hide
External Link
 Compound Name TEI-6522 Terminated [77]
External Link
 Compound Name FR-145237 Terminated [78]
External Link
 Compound Name Squalestatin 1 Terminated [79]
Synonyms
Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo
    Click to Show/Hide
External Link
 Compound Name F-12509A Terminated [80]
External Link
 Compound Name TA-993 Terminated [81]
Synonyms
MB-3, Tanabe
    Click to Show/Hide
External Link
 Compound Name Barixibat Terminated [82]
Synonyms
BARI-1453; Bile acid resorption inhibitor, Aventis; HMR-1453; 1453, Aventis
    Click to Show/Hide
External Link
 Compound Name PD-146176 Terminated [83]
Synonyms
PD 146176; 4079-26-9; 6,11-dihydrothiochromeno[4,3-b]indole; 6,11-Dihydro[1]benzothiopyrano[4,3-b]indole; CHEMBL180917; pd146176; NSC168807; 6,3-b]indole; NSC 168807; AC1L6RUM; 6,11-Dihydro-5-thia-11-aza-benzo(a)fluorene; SCHEMBL1986281; ZINC6892; CTK4I3773; AOB5548; MolPort-003-959-269; BCP24885; BS0260; BDBM50208823; MFCD05664738; AKOS024457313; NSC-168807; [1]Benzothiopyrano[4, 6,11-dihydro-; NCGC00165868-01; B7208; PD 146176, &gt; (1)Benzothiopyrano(4,3-b)indole, 6,11-dihydro-
    Click to Show/Hide
External Link
 Compound Name BIBB-515 Terminated [84]
Synonyms
BIBB 515; 156635-05-1; UNII-CG2Q6688S4; CHEMBL417571; CG2Q6688S4; (4-Chloro-phenyl)-{4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-methanone; (4-chloro-phenyl)-(4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl)-methanone; AC1L9UY8; SCHEMBL3676833; CTK8E8258; DTXSID00333401; MolPort-009-019-333; ZINC598970; BDBM50128071; RT-011501; J-009325; 1-(4-Chlorobenzoyl)-4-((4-(2-oxazolin-2-yl) benzylidene))piperidine; Piperidine, 1-(4-chlorobenzoyl)-4-((4-(4,5-dihydro-2-oxazolyl)phenyl)methylene)-
    Click to Show/Hide
External Link
 Compound Name LF-7-0165c Terminated [85]
External Link
 Compound Name SDZ-267-489 Terminated [86]
External Link
 Compound Name WAY-121898 Terminated [87]
Synonyms
136100-14-6; 1-Piperidinecarboxylic acid, 4-methyl-, 4-phenoxyphenyl ester; ACMC-20mw0l; SCHEMBL2597837; CHEMBL267052; ZINC14493; CTK0F3948; DTXSID30430876; 4-PHENOXYPHENYL 4-METHYL-1-PIPERIDINECARBOXYLATE
    Click to Show/Hide
External Link
 Compound Name SR12813 Terminated [88]
Synonyms
SR 12813; 126411-39-0; SR-12813; CHEBI:77317; GW 485801; CHEMBL458767; [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol; Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate); [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; SRL; 1ilh; AC1L9JHO
    Click to Show/Hide
External Link
 Compound Name CP-230821 Terminated [89]
External Link
 Compound Name T-686 Terminated [90]
Synonyms
PAI-1 inhibitor, Tanabe
    Click to Show/Hide
External Link
 Compound Name RPR-101821 Terminated [91]
External Link
 Compound Name MDL-29311 Terminated [92]
Synonyms
MDL-27272; MDL-29097
    Click to Show/Hide
External Link
 Compound Name CP-83101 Terminated [93]
Synonyms
AC1O5PZP; SCHEMBL1660808; SCHEMBL1660809; 3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate; methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate; 6,8-Nonadienoic acid, 3,5-dihydroxy-9,9-diphenyl-, methyl ester, (R*,S*-(E))-(+-)-
    Click to Show/Hide
External Link
 Compound Name INCB3344 Terminated [94]
Synonyms
INCB-3268; INCB-3344; PF-4254196; CCR2 antagonists, Incyte/Pfizer
    Click to Show/Hide
External Link
 Compound Name CGS-23425 Terminated [95]
Synonyms
CHEMBL46882; N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-phenyl]-oxamic acid; cgs23425; SCHEMBL281877; DTXSID7040998; NOCAS_40998; CGS 23425; BDBM50036402; AKOS027327083; N-[4-(4-Hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-oxalamic acid; N-[3,5-dimethyl-4-(4''-hydroxy-3''-isopropylphenoxy)phenyl]oxamic acid; ({4-[4-hydroxy-3-(propan-2-yl)phenoxy]-3,5-dimethylphenyl}amino)(oxo)acetic acid
    Click to Show/Hide
External Link
 Compound Name RP-73163 Terminated [96]
Synonyms
CHEMBL434418; BDBM50106700
    Click to Show/Hide
External Link
 Compound Name Astenose Terminated [97]
Synonyms
GM-1077; GMI-077
    Click to Show/Hide
External Link
 Compound Name S-12340 Terminated [98]
Synonyms
S12340; S 12340; 144754-35-8; SCHEMBL4782175; 8-(3-(3,5-Diterbutyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 8-(3-(3,5-Di-tert-butyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 1-Oxa-3,8-diazaspiro(4.5)decan-2-one, 8-(3-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)propyl)-
    Click to Show/Hide
External Link
 Compound Name ZD-9720 Terminated [99]
Synonyms
ZD-7851
    Click to Show/Hide
External Link
 Compound Name IL1aQb Terminated [100]
Synonyms
IL1aQb therapeutic vaccines (atherosclerosis); CYT-018-IL1aQb; IL1aQb therapeuticvaccines (atherosclerosis), Cytos; Immunodrug vaccines (atherosclerosis), Cytos
    Click to Show/Hide
External Link
 Compound Name NTE-122 Terminated [101]
Synonyms
ACAT inhibitor, Nissin Food
    Click to Show/Hide
External Link
 Compound Name B-5354a Terminated [102]
Synonyms
B-5354b; B-5354c; Sphingosine kinase inhibitors, Sankyo
    Click to Show/Hide
External Link
 Compound Name F-2833 Terminated [103]
Synonyms
107430-45-5; F 2833; 2-[4-(2-chlorophenyl)phenyl]propan-2-ol; AC1L3UIQ; (2-Chloro-2'-(1,1')-4-biphenyl)-2-propanol; SCHEMBL10802061; DTXSID80148050; f2833; (1,1'-Biphenyl)-4-methanol, 2'-chloro-alpha,alpha-dimethyl-
    Click to Show/Hide
External Link
 Compound Name LF-13-0491c Terminated [104]
External Link
 Compound Name FR-129169 Terminated [105]
External Link
 Compound Name AM-1101 Investigative [16]
Synonyms
Lactosylceramide synthase inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals; GAL T-2 inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals
    Click to Show/Hide
External Link
 Compound Name Apovasc Investigative [16]
Synonyms
CM-121; CM-125; CM-121 + CM-125
    Click to Show/Hide
External Link
 Compound Name KY-382 Investigative [106]
External Link
 Compound Name Adiponectin mimetics Investigative [16]
Synonyms
Adiponectin mimetics (oral, type 2 diabetes/atherosclerosis/muscle metabolic diseases)
    Click to Show/Hide
External Link
 Compound Name HL-135 Investigative [16]
External Link
 Compound Name KM-011 Investigative [16]
Synonyms
Apo-A1 mimetic peptide (atherosclerosis), KineMed; Apolipoprotein-A1 mimetic peptide (atherosclerosis), KineMed
    Click to Show/Hide
External Link
 Compound Name VULM-1457 Investigative [106]
Synonyms
Acyl CoA cholesterol acyltransferase inhibitor (dyslipidemia/atherosclerosis), Univerzity Komenskeho v Bratislave
    Click to Show/Hide
External Link
 Compound Name ARI-1778 Investigative [16]
Synonyms
KH-01503; Rev-D-4F; Reverse-D-4F; Apo-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 agonist (atherosclerosis), Abbott; Apolipoprotein-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Abbott; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Kos Pharmaceuticals; Apo-A1 agonist (atherosclerosis), Abbott/Arisaph
    Click to Show/Hide
External Link
 Compound Name GSK-1344386B Investigative [107]
Synonyms
CCR2 antagonist (atherosclerosis); CCR2 antagonist (atherosclerosis), GlaxoSmithKline
    Click to Show/Hide
External Link
 Compound Name SCH-602539 Investigative [108]
Synonyms
UNII-7467O90MW3; CHEMBL1270738; 7467O90MW3; SCH602539; 618385-42-5; SCHEMBL8058894; BDBM50329618; Carbamic acid, N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)furan-6-yl)-, ethyl ester; Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(2,3'-bipyridin-6'-yl)vinyl)-1-methyl-3-oxododecahydronaphtho(2,3-C)furan-6-yl}carbamate; Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)fura
    Click to Show/Hide
External Link
 Compound Name Radiolabeled VEGF Investigative [16]
Synonyms
Lu-scVEGF; Radiolabeled VEGF (cancer); Radiolabeled VEGF (cancer), Sibtech/Stanford; Technetium-99m-HYNIC-VEGF; Technetium-99m-single chain-VEGF; Lu-177-DOTA-PEG-scVEGF; 99mTc-HYNIC-VEGF; 99mTc-singlechain-VEGF
    Click to Show/Hide
External Link
 Compound Name AG-4070 Investigative [16]
Synonyms
LXR agonists (atherosclerosis); LXR agonists (atherosclerosis), F.Hoffmann-La Roche
    Click to Show/Hide
External Link
 Compound Name Integrin alpha-V/beta-3 receptor mab Investigative [16]
Synonyms
Integrin alpha-V/beta-3 receptor mAb (atherosclerosis); Integrin alpha-V/beta-3 antagonist (atherosclerosis), Vascular Pharmaceuticals; Integrin alpha-V/beta-3 receptor mAb (atherosclerosis), Vascular Pharmaceuticals
    Click to Show/Hide
External Link
 Compound Name ICI-245991 Investigative [16]
External Link
 Compound Name MK-6892 Investigative [109]
Synonyms
Nicotinic acid 1 receptor (GPR109A) agonists, Merck
    Click to Show/Hide
External Link
 Compound Name BMS-753951 Investigative [16]
Synonyms
Gadolinium chelate MR imaging agent (atherosclerosis), BMS
    Click to Show/Hide
External Link
 Compound Name TGFTX-1 Investigative [16]
External Link
 Compound Name INV-400 Investigative [16]
Synonyms
INV-403; INV-404; INV-405; Invasc-400 series; SREBP transcription factor 2 stimulator (atherosclerosis), InVasc; Sterol regulatory element-binding protein 2 stimulator (atherosclerosis), InVasc
    Click to Show/Hide
External Link
 Compound Name GX-401 Investigative [16]
External Link
 Compound Name RP-805 Investigative [16]
Synonyms
Matrix metalloproteinase inhibitor (atherosclerosis); Matrix metalloproteinase inhibitor (atherosclerosis), Lantheus; RP-782-111In; Indium-111-RP-782; Technetium-99m-RP-805; Matrix metalloproteinase (MMP) inhibitor (tumor imaging), Bristol-Myers Squibb; 111In-RP-782; 99mTc-RP-805
    Click to Show/Hide
External Link
 Compound Name RXP-470 Investigative [110]
Synonyms
MMP-12 inhibitors (atherosclerosis); MMP-12 inhibitors (atherosclerosis), CEA; RXP-470 derivatives (atherosclerosis), CEA
    Click to Show/Hide
External Link
 Compound Name 2NTX-99 Investigative [16]
Synonyms
Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), Nile; Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), University of Milano
    Click to Show/Hide
External Link
 Compound Name BAY-1006451 Investigative [16]
Synonyms
[18F]-BAY-1006451
    Click to Show/Hide
External Link
References
Ref 1 Silencing METTL3 Stabilizes Atherosclerotic Plaques by Regulating the Phenotypic Transformation of Vascular Smooth Muscle Cells via the miR-375-3p/PDK1 Axis. Cardiovasc Drugs Ther. 2022 Jun 15. doi: 10.1007/s10557-022-07348-6. Online ahead of print.
Ref 2 Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94. doi: 10.1007/s10517-019-04655-1. Epub 2019 Nov 25.
Ref 3 PDK1 disruptors and modulators: a patent review. Expert Opin Ther Pat. 2015 May;25(5):513-37. doi: 10.1517/13543776.2015.1014801. Epub 2015 Feb 15.
Ref 4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1596).
Ref 5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023729)
Ref 6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8400).
Ref 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7797).
Ref 8 ClinicalTrials.gov (NCT00151788) Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.. U.S. National Institutes of Health.
Ref 9 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024862)
Ref 10 ClinicalTrials.gov (NCT00783081) Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication. U.S. National Institutes of Health.
Ref 11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7838).
Ref 12 VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol. 2014 Jan;175(1):126-37.
Ref 13 ClinicalTrials.gov (NCT02108262) A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.. U.S. National Institutes of Health.
Ref 14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5785).
Ref 15 ClinicalTrials.gov (NCT01388816) A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels. U.S. National Institutes of Health.
Ref 16 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 17 ClinicalTrials.gov (NCT00851500) A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis. U.S. National Institutes of Health.
Ref 18 ClinicalTrials.gov (NCT01645306) Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02). U.S. National Institutes of Health.
Ref 19 DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
Ref 20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5594).
Ref 21 ClinicalTrials.gov (NCT00367692) Study Evaluating PSI-697 in Patients With Scleritis. U.S. National Institutes of Health.
Ref 22 ClinicalTrials.gov (NCT00985478) First in Man Study With SLV342. U.S. National Institutes of Health.
Ref 23 Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J Med Chem. 2008 Nov 27;51(22):7161-8. doi: 10.1021/jm800799q.
Ref 24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002679)
Ref 25 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012886)
Ref 26 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029634)
Ref 27 ClinicalTrials.gov (NCT01651273) A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia. U.S. National Institutes of Health.
Ref 28 ClinicalTrials.gov (NCT00796575) Effects of Multiple Doses of CS-8080 in Healthy Volunteers. U.S. National Institutes of Health.
Ref 29 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
Ref 30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7376).
Ref 31 ClinicalTrials.gov (NCT00836602) Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects. U.S. National Institutes of Health.
Ref 32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034993)
Ref 33 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
Ref 34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6696).
Ref 35 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1595).
Ref 36 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012887)
Ref 37 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005302)
Ref 38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008445)
Ref 39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010688)
Ref 40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008143)
Ref 41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000343)
Ref 42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004425)
Ref 43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021613)
Ref 44 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008868)
Ref 45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019399)
Ref 46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025539)
Ref 47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020582)
Ref 48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012486)
Ref 49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025537)
Ref 50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025982)
Ref 51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004102)
Ref 52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014823)
Ref 53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025540)
Ref 54 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015443)
Ref 55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004661)
Ref 56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001648)
Ref 57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012955)
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025541)
Ref 59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003109)
Ref 60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025536)
Ref 61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022118)
Ref 62 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
Ref 63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015904)
Ref 64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033616)
Ref 65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030801)
Ref 66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017234)
Ref 67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003719)
Ref 68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011586)
Ref 69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004510)
Ref 70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003702)
Ref 71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001538)
Ref 72 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005136)
Ref 73 Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996 Jan;37(1):148-58.
Ref 74 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010990)
Ref 75 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004635)
Ref 76 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001910)
Ref 77 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004501)
Ref 78 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006465)
Ref 79 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3057).
Ref 80 F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J Antibiot (Tokyo). 2000 May;53(5):459-66. doi: 10.7164/antibiotics.53.459.
Ref 81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003139)
Ref 82 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017452)
Ref 83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010267)
Ref 84 Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.
Ref 85 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005472)
Ref 86 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009165)
Ref 87 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003268)
Ref 88 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2763).
Ref 89 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004500)
Ref 90 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008057)
Ref 91 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006470)
Ref 92 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001533)
Ref 93 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000245)
Ref 94 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 777).
Ref 95 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007178)
Ref 96 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003588)
Ref 97 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003704)
Ref 98 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004423)
Ref 99 Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9.
Ref 100 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021743)
Ref 101 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008195)
Ref 102 B-535a, b and c, new sphingosine kinase inhibitors, produced by a marine bacterium; taxonomy, fermentation, isolation, physico-chemical properties and structure determination. J Antibiot (Tokyo). 2000 Aug;53(8):753-8.
Ref 103 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001907)
Ref 104 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
Ref 105 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002683)
Ref 106 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
Ref 107 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
Ref 108 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 347).
Ref 109 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5788).
Ref 110 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).